The inflammation and abnormal scaling, flaking, and cracking of the upper layers of the skin in patients with CTCL leads to considerable itching and discomfort. Generally this can be controlled ...

Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Mycosis Fungoides. According to GlobalData, Phase I drugs for Mycosis Fungoides have an 85% phase transition ...

The next donor recruitment drives for the Marshall's Match campaign are being held this weekend - with one taking place at ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Am J Hematol. 2017;92(10):1085-1102. doi:org/10.1002/ajh.24876 National Library of Medicine. Mycosis fungoides. National Library of Medicine. Sézary syndrome. Lymphoma Research Foundation. Cutaneous B ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

Skin (cutaneous) lymphomas often manifest as a skin rash. Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma ...

In the study, 69 patients with cutaneous T-cell lymphoma, including the most common subtypes mycosis fungoides and Sézary syndrome, were given DD-cxdl for five consecutive days every 21 days.

for the treatment of mycosis fungoides or Sézary syndrome; Oxlumo, for the treatment of hyperoxaluria type 1; and Epkinly, for relapsed or refractory diffuse large B-cell lymphoma. “By ...

Drug coverage for four drugs used to treat some rare diseases was announced in Fredericton on Wednesday under a $32-million ...

Health CanadaIn Canada, 1 in 12 people live with a rare disease, and for most people affected, the cost of treatment ...